OncologyOnline.net

Oncology Xagena

A new study provides some of the strongest evidence to date that microorganisms living in the large intestine can serve as a link between diet and certain types of colorectal cancer, the lead authors ...


Ten years ago, the Adenoma Prevention With Celecoxib ( APC ) trial showed that the selective cyclooxygenase-2 ( COX-2 ) inhibitor reduced the incidence of post-polypectomy adenoma by 38% and advanced ...


Long-term, regular Aspirin ( Acetylsalicylic acid ) use was associated with reduced risk of death from several different kinds of cancers. Accumulating evidence suggests that Aspirin not only reduc ...


In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins say they have found no evidence of cytomegalovirus ( CMV ) infection and con ...


A phase II trial of Everolimus plus Octreotide LAR as first-line treatment for patients with previously untreated, well-differentiated gastroenteropancreatic NETs and NETs of lung origin, both functio ...


Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the gut ( the microbiome ) and response to immunotherapy. In the study, the ability o ...


Indoleamine 2,3-dioxygenase-1 ( IDO1 ) catalyzes the degradation of tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveilla ...


The idea that a non-Platinum therapy might artificially extend the Platinum-free interval, thereby improving outcomes in ovarian cancer patients who experience recurrence between 6 and 12 months after ...


Final results from the randomised phase III METEOR study have confirmed the superiority of Cabozantinib over Everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma ( mRCC ) ...


Immune checkpoint inhibitors rely on the presence of ongoing immune response to exert their antitumor effect. Little is known whether an age-related decline in immune function negatively influences ...


With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a study published in The American Journal of Pathology, resea ...


New patient-reported quality-of-life data from an exploratory endpoint in the pivotal phase 3 CheckMate -141 trial evaluating Nivolumab ( Opdivo ) in patients with recurrent or metastatic squamous cel ...


A treatment harnesses the immune system to shrink tumors in bladder cancer patients that cannot take the most effective chemotherapy. These are the findings of a clinical trial led by researchers at ...


Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced renal cell carcinoma were presented at the European Society for Medical On ...


Nivolumab ( Opdivo ) maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Cong ...